Navigation Links
CMC Biologics Announces Agreement With Daiichi Sankyo Company to Develop and Manufacture Antibodies
Date:10/26/2011

SEATTLE and COPENHAGEN, Denmark, Oct. 26, 2011 /PRNewswire/ -- CMC Biologics today announced the execution of an agreement with Daiichi Sankyo Co., Ltd. ('Daiichi Sankyo') to provide process development support and manufacture of several clinical-stage antibodies over a three-year period. The two companies have recently begun work on their first joint project at CMC Biologics' Bothell manufacturing facility. Specific terms of the agreement were not disclosed.

(Logo: http://photos.prnewswire.com/prnh/20110502/SF93356LOGO)

"CMC Biologics is delighted to partner with Daiichi Sankyo, a leader among pharmaceutical companies worldwide with a heritage of scientific discovery that spans more than one hundred years," noted Gustavo F. Mahler, Ph.D., Global Chief Operations Officer at CMC Biologics. "We will be working closely with Daiichi Sankyo on the development and production of antibodies over the next several years."

Junichi Koga, Ph.D., Vice President, Biopharmaceutical Technology Research Laboratories at Daiichi Sankyo, commented, "I believe CMC Biologics is the best partner for Daiichi Sankyo because of their depth of experience and excellent quality. Together we have created a responsive working relationship to bring best-in-class biologics to patients in need."

About Daiichi Sankyo

The Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, Daiichi Sankyo is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabolic therapies. Furthermore, the Daiichi Sankyo Group has created a "Hybrid Business Model," which will respond to market and customer diversity and optimize growth opportunities across the value chain. For more information, please visit www.daiichisankyo.com.

About CMC Biologics

CMC Biologics (www.cmcbio.com) is a dedicated contract biopharmaceutical manufacturing and development organization with facilities in Copenhagen, Denmark and Seattle, Washington, USA. CMC Biologics specializes in custom services for scale up and cGMP manufacture of protein-based therapeutics for preclinical, clinical trials, and in-market production. The Company's fully integrated services includes cell line development using its proprietary CHEF1® system, process and formulation development, and comprehensive analytical testing. CMC Biologics has fully segregated microbial fermentation and mammalian cell culture suites and offers stirred tank and perfusion production processes.


'/>"/>
SOURCE CMC Biologics
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pinnacle Biologics Files for Orphan Drug Designation for PHOTOFRIN® in the Treatment of Patients with Malignant Mesothelioma.
2. Senator Menendez, Lt. Governor Guadagno Unveil New Biotech Firm Oncobiologics
3. Oncobiologics, Inc. Announces Two New Agreements Worth Close to $80 Million
4. ProteinSimple to Offer Direct Sales, Service and Support for Biologics Products in Europe
5. Director of Commerce, Rogers Weed, Presided Over Ribbon Cutting Ceremony Celebrating Opening of Expanded Manufacturing Facility at CMC Biologics
6. CMC Biologics Enters Commercial Supply Agreement with Inspiration Biopharmaceuticals for IB1001
7. Pinnacle Biologics Appoints ALKOPHARMA SA Its Exclusive Distributor For PDT (Photodynamic Therapy), in Select European Countries, Middle East And South East Asian Territories
8. Aperion Biologics Invited to Present at the UBS Global Life Sciences Conference
9. CMC Biologics Adds 2,000 Liter Single-Use Bioreactor at its Copenhagen Manufacturing Facility
10. Oncobiologics, Inc. and Fox Chase Cancer Center Announce Co-Development of a Novel Cancer Therapy Platform
11. Amgen Announces PDUFA Date for XGEVA® Supplemental Biologics License Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Research and Markets has announced the addition of ... Forecast to 2022" report to their offering. ... date financial data derived from varied research sources to present ... impact on the market during the next five years, including ... sub markets, regional and country level analysis. The report provides ...
(Date:6/23/2016)... -- , , , WHEN: , ... , , , LOCATION: , , , Online, with free ... EXPERT PANELISTS:  , , , Frost & Sullivan,s Global Vice President ... Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program Manager , ... is witnessing an exceptional era. Several new demand spaces, such as ...
(Date:6/23/2016)... , June 23, 2016  Guerbet announced today that ... Supplier Horizon Award . One of ... was recognized for its support of Premier members through ... clinical excellence, and commitment to lower costs. ... this recognition of our outstanding customer service from Premier," ...
Breaking Medicine Technology:
(Date:6/27/2016)... , ... June 27, 2016 , ... "FCPX editors can ... inside of Final Cut Pro X," said Christina Austin - CEO of Pixel Film ... Final Cut Pro X users can now reveal the media of their ...
(Date:6/27/2016)... ... June 27, 2016 , ... A ... revolutionize the emergency ambulance transport experience for the millions of people who require ... has disrupted the taxi industry through the use of technology. Now, SmartEMS has ...
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A Forever Recovery, a ... and World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility is ... to some of the world’s leading providers of cereal and other breakfast foods. Its ...
(Date:6/26/2016)... ... ... Brent Kasmer, a legally blind and certified personal trainer is helping to develop a weight ... app plans to fix the two major problems leading the fitness industry today:, ... program , They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
Breaking Medicine News(10 mins):